Advances in the prevention of Alzheimer's Disease
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
Alzheimer's disease (AD), the leading cause of dementia, has reached epidemic proportions, with major social, medical and economical burdens. With no currently available curative treatments, both the World Health Organization and the G8 Dementia Summit recently identified dementia and AD prevention as a major public health priority. Dementia and AD have a wide range of risk factors (genetic, vascular/metabolic and lifestyle-related), which often co-occur and thus interact with each other. Previous intervention efforts aimed at preventing dementia and AD focused on the management of single risk factors, with relatively modest findings. Also, the effect of risk factors depends on age at exposure, indicating that the timing of preventive interventions needs to be carefully considered. In view of the complex multifactorial nature of AD, as well as its long pre-clinical (asymptomatic) phase, interventions simultaneously targeting multiple risk factors and disease mechanisms at an early stage of the disease are most likely to be effective. Three large European multidomain prevention trials have been launched with the goal of preventing cognitive decline, dementia and AD in older adults with different risk profiles. Pharmacological trials are also shifting towards prevention of Alzheimer dementia, by targeting at-risk individuals prior to the onset of cognitive symptoms. The current review will summarize and discuss the evidence on risk and protective factors from observational studies, ongoing lifestyle-related and pharmacological randomized controlled trials (RCTs), as well as future directions for dementia and AD prevention.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ng, M., Fleming, T., Robinson, M., Thomson, B., Graetz, N., Margono, C., Mullany, E. C., Biryukov, S., Abbafati, C., Abera, S. F., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60460-8 · Cited by 11,952
The global prevalence of dementia: a systematic review and metaanalysis.
Prince, M., Bryce, R., Albanese, E., Wimo, A., Ribeiro, W., & Ferri, C. P. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.11.007 · Cited by 4,941 · cited 1×
“Risk factors for dementia and Alzheimer’s disease across the lifespan (Figure modified from [51])”
Moms, J. C., Heyman, A., Mohs, R. C., Hughes, J. P., van Belle, G., Fillenbaum, G., Mellits, E. D., & Clark, C. (1989) · Neurology · doi:10.1212/wnl.39.9.1159 · Cited by 4,130
Ngandu, T., Lehtisalo, J., Solomon, A., Levälahti, E., Ahtiluoto, S., Antikainen, R., Bäckman, L., Hänninen, T., Jula, A., Laatikainen, T., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60461-5 · Cited by 3,689
Self-citationAdvancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
Dubois, B., Feldman, H. H., Jacova, C., Hampel, H., Molinuevo, J. L., Blennow, K., DeKosky, S. T., Gauthier, S., Selkoe, D., Bateman, R., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70090-0 · Cited by 3,321
Ballard, C., Gauthier, S., Corbett, A., Brayne, C., Aarsland, D., & Jones, E. (2011) · The Lancet · doi:10.1016/s0140-6736(10)61349-9 · Cited by 2,336
Jack, C. R., Albert, M. S., Knopman, D. S., McKhann, G. M., Sperling, R. A., Carrillo, M. C., Thies, B., & Phelps, C. H. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.004 · Cited by 2,042 · cited 1×
“[59–61]; the use of biomarkers, either as enrichment strategies or supportive of a disease-modifying effect”
Mixed brain pathologies account for most dementia cases in community-dwelling older persons
Schneider, J. A., Arvanitakis, Z., Bang, W., & Bennett, D. A. (2007) · Neurology · doi:10.1212/01.wnl.0000271090.28148.24 · Cited by 1,992 · cited 1×
“AD, a neurodegenerative disorder, is the leading cause of dementia, accounting for 60–70% of cases [2,3], although increasing evidence shows that mixed brain pathologies (AD and vascular) account for most dementia cases, especially in very advanced age (age 85+) [4,5].”
Revising the definition of Alzheimer's disease: a new lexicon
Dubois, B., Feldman, H. H., Jacova, C., Cummings, J. L., DeKosky, S. T., Barberger-Gateau, P., Delacourte, A., Frisoni, G., Fox, N. C., Galasko, D., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70223-4 · Cited by 1,869
Alzheimer’s disease drug-development pipeline: Few candidates, frequent failures
Cummings, J. L., Morstorf, T., & Zhong, K. (2014) · Alzheimer's Research & Therapy · doi:10.1186/alzrt269 · Cited by 1,744
Obesity and Vascular Risk Factors at Midlife and the Risk of Dementia and Alzheimer Disease
Kivipelto, M., Ngandu, T., Fratiglioni, L., Viitanen, M., Kåreholt, I., Winblad, B., Helkala, E.-L., Tuomilehto, J., Soininen, H., & Nissinen, A. (2005) · Archives of Neurology · doi:10.1001/archneur.62.10.1556 · Cited by 1,291 · cited 1×
“Some of these factors increase dementia risk when present in midlife, emphasizing the importance of applying a life-course perspective when examining risk factors and implementing preventive interventions [26-30].”
Self-citationAlzheimer’s disease: Clinical trials and drug development
Mangialasche, F., Solomon, A., Winblad, B., Mecocci, P., & Kivipelto, M. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70119-8 · Cited by 1,217
Self-citationThe age-dependent relation of blood pressure to cognitive function and dementia
Qiu, C., Winblad, B., & Fratiglioni, L. (2005) · The Lancet Neurology · doi:10.1016/s1474-4422(05)70141-1 · Cited by 1,138
Apolipoprotein E polymorphism and Alzheimer's disease
Poirier, J., Bertrand, P., Poirier, J., Kogan, S., Gauthier, S., Poirier, J., Gauthier, S., Davignon, J., Bouthillier, D., & Davignon, J. (1993) · The Lancet · doi:10.1016/0140-6736(93)91705-q · Cited by 1,108
Inflammation in Alzheimer Disease--A Brief Review of the Basic Science and Clinical Literature
Wyss-Coray, T., & Rogers, J. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006346 · Cited by 975 · cited 1×
“Various mechanisms have been described to explain the link between genetic and environmental factors and AD pathophysiology, including oxidative stress, inflammatory and vascular-related pathways [9,10].”
Physical Exercise as a Preventive or Disease-Modifying Treatment of Dementia and Brain Aging
Ahlskog, J. E., Geda, Y. E., Graff-Radford, N. R., & Petersen, R. C. (2011) · Mayo Clinic Proceedings · doi:10.4065/mcp.2011.0252 · Cited by 885
Reiman, E. M., Chen, K., Liu, X., Bandy, D., Yu, M., Lee, W., Ayutyanont, N., Keppler, J., Reeder, S. A., Langbaum, J. B. S., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0900345106 · Cited by 785 · cited 1×
“Moreover, the APOE e4 allele reduces the age of AD onset, amplifies the negative effects of lifestyle-related factors and modulates responsivity to interventions [15-20].”
Peters, R., Beckett, N., Forette, F., Tuomilehto, J., Clarke, R., Ritchie, C., Waldman, A., Walton, I., Poulter, R., Ma, S., et al. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70143-1 · Cited by 770 · cited 1×
“When collectively evaluated by the State-of-the-Science Conference held by the National Institutes of Health (NIH), it was concluded that the evidence for preventive interventions of dementia/AD was inadequate, with an exception of adequate evidence for anti-hypertensive medications [53–55].”
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
Salloway, S., Sperling, R., Gilman, S., Fox, N. C., Blennow, K., Raskind, M., Sabbagh, M., Honig, L. S., Doody, R., van Dyck, C. H., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181c67808 · Cited by 753
Schneider, L. S., Mangialasche, F., Andreasen, N., Feldman, H., Giacobini, E., Jones, R., Mantua, V., Mecocci, P., Pani, L., Winblad, B., et al. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12191 · Cited by 651
Self-citationKivipelto, M., Solomon, A., Ahtiluoto, S., Ngandu, T., Lehtisalo, J., Antikainen, R., Bäckman, L., Hänninen, T., Jula, A., Laatikainen, T., et al. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.09.012 · Cited by 589 · cited 2×
“2 years [66].”
Self-citationBateman, R. J., Aisen, P. S., De Strooper, B., Fox, N. C., Lemere, C. A., Ringman, J. M., Salloway, S., Sperling, R. A., Windisch, M., & Xiong, C. (2010) · Alzheimer's Research & Therapy · doi:10.1186/alzrt59 · Cited by 573 · cited 1×
“Genetic causes of AD include autosomal-dominant mutations in three genes (Presenilin 1 [PSEN1], Presenilin 2 [PSEN2] and the amyloid precursor protein [APP]), which are implicated in early-onset AD and account for approximately 1% of all cases [5,23,24].”
Reiman, E. M., Quiroz, Y. T., Fleisher, A. S., Chen, K., Velez-Pardo, C., Jimenez-Del-Rio, M., Fagan, A. M., Shah, A. R., Alvarez, S., Arbelaez, A., et al. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70228-4 · Cited by 541 · cited 1×
“gov NCT01998841) is a potentially label-enabling trial testing the anti-amyloid compound crenezumab (Genentech) in 300 asymptomatic members of an extended large family in Colombia with the PSEN1 E280A mutation, for which the median onset age of mild cognitive impairment (MCI) is 44 years and the onset of dementia is 4…”
Daviglus, M. L., Bell, C. C., Berrettini, W., Bowen, P. E., Connolly, E. S., Cox, N. J., Dunbar-Jacob, J. M., Granieri, E. C., Hunt, G., McGarry, K., et al. (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-153-3-201008030-00260 · Cited by 463 · cited 1×
“When collectively evaluated by the State-of-the-Science Conference held by the National Institutes of Health (NIH), it was concluded that the evidence for preventive interventions of dementia/AD was inadequate, with an exception of adequate evidence for anti-hypertensive medications [53–55].”
Midlife Coffee and Tea Drinking and the Risk of Late-Life Dementia: A Population-Based CAIDE Study
Eskelinen, M. H., Ngandu, T., Tuomilehto, J., Soininen, H., & Kivipelto, M. (2009) · Journal of Alzheimer's Disease · doi:10.3233/jad-2009-0920 · Cited by 428
Self-citationHigh total cholesterol levels in late life associated with a reduced risk of dementia
Mielke, M. M., Zandi, P. P., Sjögren, M., Gustafson, D., Östling, S., Steen, B., & Skoog, I. (2005) · Neurology · doi:10.1212/01.wnl.0000161870.78572.a5 · Cited by 411
Is dementia incidence declining?: Trends in dementia incidence since 1990 in the Rotterdam Study
Schrijvers, E. M. C., Verhaaren, B. F. J., Koudstaal, P. J., Hofman, A., Ikram, M. A., & Breteler, M. M. B. (2012) · Neurology · doi:10.1212/wnl.0b013e3182553be6 · Cited by 408
Slooter, A. J. C., Cruts, M., Kalmijn, S., Hofman, A., Breteler, M. M. B., Van Broeckhoven, C., & van Duijn, C. M. (1998) · Archives of Neurology · doi:10.1001/archneur.55.7.964 · Cited by 399 · cited 2×
“The APOE e4 allele increases the risk for AD in a dose-response manner, where those with homozygous e4 allele (two e4 copies) have a higher risk than individuals with heterozygous e4 allele (a combination of one e4 copy, and an alternative copy: e2 or e3 allele), who in turn have a higher risk than individuals with no…”
Preclinical Alzheimer disease—the challenges ahead
Sperling, R. A., Karlawish, J., & Johnson, K. A. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.241 · Cited by 291
Ritchie, K., Carriere, I., Ritchie, C. W., Berr, C., Artero, S., & Ancelin, M.-L. (2010) · BMJ · doi:10.1136/bmj.c3885 · Cited by 250 · cited 1×
“Even modest reductions in these factors can considerably mitigate total risk and delay the onset age of dementia/AD [52].”
Nagy, Z. S., Esiri, M. M., Jobst, K. A., Johnston, C., Litchfield, S., Sim, E., & Smith, A. D. (1995) · Neuroscience · doi:10.1016/0306-4522(95)00331-c · Cited by 250
Dyslipidemia and the Risk of Alzheimer’s Disease
Reitz, C. (2013) · Current Atherosclerosis Reports · doi:10.1007/s11883-012-0307-3 · Cited by 190
Vellas, B., Carrillo, M. C., Sampaio, C., Brashear, H. R., Siemers, E., Hampel, H., Schneider, L. S., Weiner, M., Doody, R., Khachaturian, Z., et al. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.03.007 · Cited by 147 · cited 2×
“More optimal designs would test the effects of treatments in heterogeneous samples while simultaneously improving and tailoring the trials for sub-populations as novel biomarkers are identified and validated [98].”
Dominantly Inherited Alzheimer Network: facilitating research and clinical trials
Moulder, K. L., Snider, B., Mills, S. L., Buckles, V. D., Santacruz, A. M., Bateman, R. J., & Morris, J. C. (2013) · Alzheimer's Research & Therapy · doi:10.1186/alzrt213 · Cited by 142
Farrer, L. A. (1997) · JAMA · doi:10.1001/jama.1997.03550160069041 · Cited by 124
Johansson, L., Guo, X., Hällström, T., Norton, M. C., Waern, M., Östling, S., Bengtsson, C., & Skoog, I. (2013) · BMJ Open · doi:10.1136/bmjopen-2013-003142 · Cited by 101
(2013) · Journal of Alzheimer’s Disease · doi:10.3233/jad-132372 · Cited by 72
Cited by
Shining light on the head: Photobiomodulation for brain disorders
Hamblin, M. R. (2016) · BBA Clinical · doi:10.1016/j.bbacli.2016.09.002 · Cited by 627
Santos, C. Y., Snyder, P. J., Wu, W., Zhang, M., Echeverria, A., & Alber, J. (2017) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1016/j.dadm.2017.01.005 · Cited by 431
Prevention of dementia in an ageing world: Evidence and biological rationale
Grande, G., Qiu, C., & Fratiglioni, L. (2020) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101045 · Cited by 229
Kehoe, P. G. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-171119 · Cited by 133
Mullane, K., & Williams, M. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.09.026 · Cited by 98
Metadata
- Authors
- Sindi, S., Mangialasche, F., & Kivipelto, M.
- Venue
- F1000Prime Reports
- Publisher
- Faculty Opinions Ltd
- Published
- 2015-05-12
- Volume
- 7
- Pages
- 50-50
- ISSN
- 2051-7599 (ISSN-L)
- OpenAlex
- W2406302344
- Cited by
- 109
- References
- 37
- FWCI
- 12.78
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.